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A population of guinea pig epidermal cells, identified 
a s L angerhans cells, formed rosettes with sheep eryth-
rocytes coated with lgM immunoglobulin and C3b 
(EACl-3b) but not with intermediates carrying only CI, 
CI4b, or Cl4b2a. These findings were unusual since most 
other cells expressing C3b receptors also express C4b 
r eceptors . To investigate whether these results were the 
consequence of a limited number of C4b molecules on 
the cells , EACI4b ce lls were prepared with increased 
a mounts ofC4b (15 to 250 J-l.g on 1011 cells). EACI4b rosette 
for m a tion was found with a maximal number when there 
w er e 3,000 molecules per cell, a 6-fold excess over that 
found in previous experiments. One could inhibit this 
r osette formation by fluid phase C3b as well as by fluid 
phase C4b, suggesting proximity or possible identity of 
these 2 receptors. 
Membrane receptors for products of complement activation 
are widely distributed among cells in most mammalian tissues. 
The specificity of these receptors for certain complement com-
ponents as well as for their fragments vary among cells, and the 
same cell may simultaneously express separate receptors for 
different components or fragments. 
Many of the biological effects of complement are mediated 
by the interaction of these cell membrane receptors with acti-
va ted complement components. This association between cells 
and complement components is predominantly a consequence 
of complement activation in the microenvironment of the cell. 
Our understanding of the role of complement in fighting infec-
tion by microorganisms and of the relationship of complement 
to other elements in the immune system has increased in recent 
years. The complement system, which was originally described 
only as a cell lysis inducer, is now known to be of greater 
importance because it has a role in the enhancement of 
phagocytosis, inflammation , antigen focusing, and specific re-
sponses in relation to intercell cooperation . 
COMPONENTS OF COMPLEMENT REQUIRED FOR 
MEMBRANE COMPLEMENT RECEPTOR 
INTERACTION 
The nature of the components of the complement system 
and the fragments required for receptor interaction is presently 
under extensive investigation. Cleavage of C3 is central to the 
function of the complement system; C3 is present in greater 
concentration than all the other components, and its activation 
or cleavage is a prerequisite to the functioning of the system. 
This activation can ·take place by 2 distinct pathways. The 
difference between these pathways lies in the manner in which 
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they are initially activated, though they share a common final 
attack mechanism: the assembly of the C5b,6,7,8,9 complex that 
is responsible for membrane damage [1,2]. 
The first mode of complement activation, known as the 
classical pathway, is mediated by antigen-antibody aggregates. 
Attachment of the C1q portion of C1 to the Fe fragment of the 
immunoglobulin leads to activation of C1 (Cl) and to its trans-
formation to an active protease [3]. In a process of limited 
proteolysis, CI catalyses the activation of both C4 [ 4] and C2 
[5], which combine to form the thermolabile enzyme C4b2a 
[6] . This enzyme is also known as C3 convertase because it 
activates C3 (Fig 1) . 
The second mechanism of complement activation, the alter-
native pathway, can be activated by immunoglobulins, although 
it can function without them and is independent of C1, C4, and 
C2 utilization [7]. Cleavage of C3 by this pathway occurs in at 
least 2 distinct phases: continuous generation of C3b by low-
grade cleavage of C3 [8] (probably by proteolytic enzymes in 
serum) and subsequent cleavage of C3 by the interaction of 
C3b,B,f> and properdin [9]. Transition to C3b-dependent am-
plification is necessary to achieve substantial C3 cleavage (Fig 
1). 
Regardless ofthe pathway involved, C3 is cleaved to generate 
a small fragment C3a with anaphylotoxic activity [10] and a 
larger fragment C3b. Similarly, cleavage of C4 by CI leads to 
the formation of a small fragment C4a and a larger fragment 
C4b. Both C4b and C3b are unstable. Unless they bind imme-
diately to complexes or membranes, they undergo conforma-
tional changes so that the binding sites are lost and these 
molecules remain in the fluid phase. The C4b and C3b, either 
already bound to surfaces or free in the fluid phase, can then 
bind to certain cells that possess specific receptors for them. 
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The 2 major fragment products of C4 and C3 activation, C4b 
and C3b, are central to the formation of the classical (C4b2a) 
and alternative (C3bBb) pathway convertases and therefore 
require stringent regulation to prevent inappropriate activation. 
Mechanisms for the control of formation and function of these 
2 enzymes have been discerned [11,12]. Of relevance here is the 
enzyme C3b inactivator (C3biNA), originally described to act 
on C3b and now also known to act on C4b. The ability of C4b 
and C3b to form either the C4b2a or the alternative pathway 
convertase is abolished by the proteolytic action of the C3blNA, 
which in the presence of 1 of 2 cofactors, C4-binding protein 
(C4-bp) [12] or ,B1H [13], results in the cleavage of the c/ chains 
of C4b and C3b, respectively, to yield inactive products (Fig 2) . 
The inactive product of C3b, C3bi, requires the subsequent 
attack by trypsin-like enzymes that liberate C3d [14]. Although 
it does not continue in the complement sequence, C3d can bind 
to certain cell receptors. This 2-step reaction does not seem to 
occur with C4b, and liberation of C4d and C4c appears to be 
accomplished with C4-bp and C3biNA alone. 
CLASSIFICATION OF COMPLEMENT RECEPTORS 
The observation that immune complexes as well as microor-
ganisms treated with antibody in the presence of complement 
adhere to certain nonsensitized indicator particles such as hu-
man erythrocytes was the first indication that mammalian cells 
had membrane receptors for altered complement components. 
This reaction, termed immune adherence [15], was shown to be 
mediated through C3b [16]. Subsequently, it was demonstrated 
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FIG 2. Generation of C4c and C4d from C4b as well as C3c and C3d 
from C3b by the action of the C3INA and the cofactors ,BlH and C4-
bp. 
that C3b receptors had a widespread tissue distribution (Table 
I) and could be detected on the surfaces of primate erythrocytes 
[17], many nonprimate platelets [17], polymorphonuclear leu-
kocytes [39], macro phages [34) , monocytes [ 40), a subpopula-
tion of lymphocytes (primarily B cells) [27], mast cells [35], 
eosinophils [21,22], and the epithelial cells of normal renal 
glomeruli [18,38). The C3b receptors on many of the above cells 
also react with C4b. Erythrocytes, lymphocytes, and some 
lymphoblastoid cells have been shown to have C4b as well as 
C3b receptors. The possible identity of these 2 receptors is 
indicated by the fact that on these cells the 2 receptors co-cap 
[27] and the fact that fluid-phase C3b or C4b can inhibit rosette 
formation. However, the affinity for C4b seems to be less than 
for C3b since more C4b is required per erythrocyte than C3b to 
give a maximal number of rosettes [ 41). Recognition of the C3b 
receptor for C4b is presumably a reflection of structural simi-
larities between C3b and C4b molecules. 
In normal serum C3b is further degraded, first to C3bi, then 
to C3d [13,14) (Fig 2) . The biological activity of the C3d product 
differs from that of C3b. It no longer participates in complement 
activation, nor can it bind to certain cells. Erythrocytes [19], 
differentiated plasma cells [29], neutrophils [36), platelets 
[17], and the renal glomerulus [38] do not express receptors for 
C3d, though a small proportion of normal B lymphocytes [27), 
certain lymphoblastoid cells [24-26], eosinophils [21], mono-
cytes [18,20], and macrophages [20,33,34) do bind C3d (Table 
I). This was first recognized by Ross et al [ 42), who showed 
that normal lymphocytes bind more erythrocyte-complement 
complexes prepared with purified human components than 
those prepared with whole mouse serum. Addition of C3biNA 
to erythrocyte-complement complexes causes loss of binding of 
human intermediates by normal lymphocytes, an indication 
that the decreased binding of mouse intermediates is due to 
conversion of C3b to C3d by the C3biNA in the mouse serum. 
The existence of only the C3d and not the C3b receptor has 
been demonstrated on Daudi cells (cultivated from Burkitt's 
lymphoma) , which bind only mouse and not human interme-
diates [ 43). 
Native C3 does not bind to the C3b receptor on normal cells, 
though with certain lymphoblastoid cells, notably Raji cells, it 
has been claimed that native C3 can bind to and block the 
complement receptor [44). However , this finding may reflect 
the ability of certain membrane-associated enzymes to cleave 
C3. 
Complement Receptors on Langerhans Cells 
Sting! et al [ 45) demonstrated that human Langerhans cells 
(LCs) bear Fe receptors for immunoglobulins and that they 
form rosettes with erythrocytes sensitized with specific IgM 
antibody only after incubation with whole mouse serum, an 
indication that they have complement receptors. In view of the 
variety of complement receptors present on mammalian cells, 
Berman and Gigli [ 46) attempted further characterization of 
the complement receptors on LCs. 
Hartley guinea pig epidermal cells (GPECs) , prepared as 
described by Sting! et al [45], were 4% to 5% LCs as demon-
strated by positive 5' -adenosinetriphosphatase (ATPase) stain-
ing of the cell membrane. Of these GPECs in single-cell sus pen-
TABLE I. Complement receptors on mammalian cells 
Receptor present 
Cell type Reference 
C3b C3b i C3d C4 b 
Erythrocytes 
primates only + + [17,18,19,20] 
other mammals (17] 
Eosinophils-human" + + + [21,22] 
Lymphoblastoid-cells • 
human, Burkitt's lymphoma 
Daudi cells + [24] 
R aji cells + 
B lymphocytes-human 
+ + [25,26] 
peripheral + + + + [1 8,27] 
human plasma cell [28,29] 
human tonsil + + (27] 
T lymphcoytes 
human peripheral [30,3 1] 
phytohemagglutinin-stimulated [32] 
human peripheral + + + 
Mac rophages·· 
guinea pig peritoneal exudate + + [33] 
human a lveolar + + [34] 
human peripheral + + (20] 
Mast cells-rat 
peritoneal + + + [35] 
Monocytes 
human pe ripheral + + + [l8,20] 
Neutrophils 
hmnan rnature + + [27,36] 
human immature + + + [37] 
Platelets 
primutes + [1 7] 
non primates (17] 
Renal glomeruli 
human + + (18,38] 
" Mouse peripheral and spleen eosinophils have been reported to have no C3b 
or C3d receptors [23]. 
• This table does not include most of the lymphoblast.o id cell types t hat have 
been studi ed in individual -patienlS or in cul tured cell lines, or the studies done on 
animals other than gui nea pigs. 
' Mouse peripheral , spleen, and resident peritoneal macrophages have both 
C3b and C3d receptors; mouse peritoneal exudate macrophages have only C3b 
receptors [23]. 
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sion, 2.6% could form rosettes with EAigMCl-3b. No rosette 
formation occurred with sheep erythrocytes, EAigM, 
EAigMCI, EAigMCI4, EAigMC4, or EAigMCI,4,2. That LCs 
were indeed the cells involved in C3 rosette formation was 
determined by electron microscopy: Erythrocytes coated with 
C3b were seen in close apposition to the membranes of LCs 
with their characteristic lobulated nuclei and intracytoplasmic 
granules. Depletion of LCs from the GPECs by rosetting with 
bovine erythrocytes coated with IgG and removal of the rosettes 
with ficoll-hypaque gradient centrifugation resulted in a prep-
aration that was only 0.8% LCs by ATPase positivity and 0.6% 
LCs by Fe rosetting. These cells gave only 0.4% rosettes with 
C3b-coated sheep erythrocyte complexes. On the other hand, 
enrichment of LCs by removal of t he GPECs not adhering to 
collagen-coated tissue culture dishes resulted in a suspension of 
cells that was 9.9% positive for ATPase, 10.9% positive for Fe 
rosettes, and 10.0% positive for complement rosettes. 
The fact t hat LCs have C3b receptors was further demon-
strated when C3b rosette formation was blocked by preincu-
bation of the GPECs with human serum treated with zymosan 
(to produce fluid-phase C3b via the alternative pathway) or 
with less concentrated purified human C3b. This resulted in 
100% and 80% inhibition of C3b rosette formation, respectively, 
while control cells preincubated with normal human serum or 
purified C3 there was only 6% or 0% blocking, respectively. 
After preincubation with zymosan-treated human serum as a 
source of C3b, or purified human C3b, a percentage of GPECs 
showed C3b on their surfaces by positive immunofluorescence 
with goat anti-human-C3-IgG conjugated with fluorescein iso-
thiocyanate. This percentage correlated with that obtained for 
Fe and C3b rosettes in t he cell preparation prior to preincuba-
tion. 
T he fact that LCs seemed to express receptors for C3b bu t 
not for C4b was unusual since most other cell types possessing 
C3b receptors also have C4b receptors. In previous studies with 
radiolabeled C3b and C4b on complement-coated erythrocytes, 
it had been shown that human peripheral B lymphocytes have 
a greater affinity for C3b than for C4b [41]; therefore, EAClb 
cells were prepared with increasing amounts of C4b (15 to 250 
JLg x 109 cells). 
Table II shows that an optimal number of rosettes are formed 
when the EACl414b cells were prepared with 130 JLg of C4b on 
109 cells, corresponding to 3,100 C4b protein molecules per 
erythrocyte complex. Fewer rosettes formed when there were 
6,000 C4b molecules per cell, possibly because there is dissocia-
tion of t he C4b from the erythrocyte surface* and consequently 
fluid-phase inhibition of the rosetting. 
The proximity of the C3b and C4b receptors on the LCs and 
their probable identity was investigated by inhibition of the 
formation of the C4b rosettes by fluid -phase C3b, which was a 
more effective inhibitor than C4b itself (Table III). 
Since there are 2 populations of mammalian cells, those with 
both C3b-C4b as well as C3d-C4d receptors and those with only 
the former, it was of interest to see wh ether LCs have the C3d-
C4d receptors. Treatment of EAigMCl414b complexes with 
C4-bp and C3biNA cleaved the C4b on the erythrocyte m em -
* Chu V, Gigli I, unpublished data. 
Note on Nomenclature 
The nomenclature conforms to that agreed upon by the World 
Health Organization (Bull WHO 38:935, 1968). Fragments of individual 
components of complement are indicated as subscripts 
C4b,C4d,C3b,C3bi,C3d. The activated state of a component in the fluid 
phase is signified by a bar above the component number. 
Sheep erythrocytes are sensitized with rabbit anti-sheep lgG or lgM 
to give EAigG and EAigM, respectively. These are reacted with indi-
vidual components of complement sequentially to give (in the latter 
case) EAigMCI; EAlgMC4b; EAlgMCl4b; EAigMC14d; EAigMCl,4,2; 
EAlgMCl,4,2,3b or EAlgMCl-3b. Both EAigGC3 and EAlgMC3 refer 
to the products of reaction with whole mouse serum rather than the 
products of reaction with purified complement components. 
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TABLE II. Demonstration of C4b rosette formation with a 
preparation of g uinea pig epiderm al cells enriched in Langer hans 
cells" 
Intermediate Molecules of fig C4b/ 10
9 Cells 
C4b/erythrocyte erythrocytes rosetted (%) 
EAigM 2.0 
EAigMCI 0.6 
EAlgMCl4b 350 15 0.2 
2,100 90 6.0 
3,100 130 8.4 
6,000 250 7.0 
"The guinea pig epidermal cells (GPECs) were enriched in Langer-
hans cells by equilibrium density centrifugation for 20 min at 6,927 xg 
in bovine serum albumin (density = 1.060 to 1.080) as described by 
Steinman and Cohn (47]. The result was a preparation 16% ATPase-
positive with 7.0% Fe rosettes (bovine erythrocytes coated with rabbit 
anti-bovine IgG). Duplicate samples of GPECs were incubated in 
gelatin dextrose verona! barbitol buffer with calcium and magnesium 
at a final concentration of 1.5 to 2.0 X 106 viable cells/ c" with the 
erythrocyte complexes in a ratio of 1:50 at 37°C for 5 min, pelleted for 
5 min at 200 xg, incubated for 30 min at 37°C, and then incubated for 
90 min at 0°C. The rosettes were gently resuspended, and about 5 x 
104 GPECs were spun into 60-mm coverslips and treated with Wright's 
stain. More than 1,000 GPECs were counted for each sample; those 
with ~ 4 EAigM, EAlgMCI, or EAigMCl414b touching the surface 
were counted as rosettes. 
TABLE III. Fluid-phase inhibition of EAlgMCI414b rosette 
formation" 
Treatment of Intermediate GPECs · 
GDVB++ EAigM 
GDVB++ EAigMCI 
GDVB++ EAlgMCl414b 
C4b EAigMCl414b 
C3b EAigMCl414b 
Cells 
rosetted (%) 
2.4% 
1.2% 
8.4% 
4.5% 
2.8% 
Inhibi tion 
(%) 
54% 
78% 
" The GPECs were enriched in Langerhans cells as described in 
Table II. The result was a preparation 20% ATPase-positive with 11.0% 
Fe rosettes (bovine erythrocytes coated with rabbit anti-bovine IgG) . 
Duplicate samples of GPECs were incubated first at 37°C for 15 min 
then at 0°C for 15 min in GDVB++ (control), in fluid-phase C4b 
(obtained from the supernatant in the formation of EACl --> EAC14b 
with 3,100 molecules of C4b/erythrocyte) or in fluid-phase C3b (ob-
tained from the supernatant of the reaction between EAigMC142 
complexes and C3). The C4b and C3b were used within 48 hr after their 
preparation. They were adjusted to equal protein concentrations after 
the initial protein concentration had been found through tracing of the 
dye density of the polyacrylamide gel after electrophoresis. The prein-
cubated GPECs were then washed in GDVB++ and rosetted with 
EAC14b complexes in a ratio of 1:50 as described in Table II. 
Abbreviations: GDVB++, gelatin dextrose verona! barbitol buffer 
with calcium and magnesium; GPECs, guinea pig epidermal cells. 
brane; C4c was thereby released into the supernatan t and C4d 
was left on the erythrocyte surface, as demonstrated by auto-
radiography of the membrane proteins after electrophoresis in 
sodium dodecyl sulfate-urea-dithiothreitol. As can be seen in 
Table IV, 8.3% of the GPECs formed rosettes with EAigMCl4d· 
the percentages of Fe and EAigMCl4b rosettes were 7.5% ancl 
8.7%, respectively. These experiments demonstrated that LCs 
possess receptors for C4d as well as receptors for C3b-C4b. 
IMMUNOLOGIC SIGNIFICANCE OF COMPLEMENT 
RECEPTORS 
The significance of complement receptors on the cells that 
possess them is well recognized . Both in vivo [ 48,49] and in 
vitro [50,51] evidence indicates that the complement system, in 
particular C3, is involved in increased adherence and subse-
quent ingestion of bacteria (opsonization) and killing by poly-
mor phonuclear and mononuclear phagocytes. The fact that C3 
is important in the host defense is illustrated by the finding 
that individuals whose serum lacks C3 are unable to opsonize 
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TABLE IV. Demonstration of C4d rosette formation with a 
preparation of guinea pig epidermal cells enriched in Langer hans 
cells" 
Intermedia te 
EAigM 
EAigMCi 
EAigMCl414b 
EAigMCl414d 
Cells rose tted (%) 
1.6% 
0.7% 
8.7% 
8.3% 
"The guinea pig epidermal cells (GPECs) were enriched in Langer-
hans cells as described in Table II. The result was a preparation 14% 
ATPase-positive with 7.5% rosettes (bovine erythrocytes coated with 
rabbit anti-bovine IgG). The EAigMCi414d cells were made by incu-
bation of EAigMCi414b cells with C4-binding protein and C3b inacti-
vator in gelatin dextrose verona! barbitol buffer with calcium and 
magnesium (GDVB++) for 60 min at 37°C followed by 3 washings in 
GDVB++ at 4°C. Rosettes with GPECs were formed and counted as 
described in Table II. 
bacteria in vitro and therefore are susceptible to frequent and 
often life-threatening infections [ 48-50]. The adherence reac-
tions mediated by complement are also biologically relevant to 
the induction of allergic inflammation. 
The exact mechanism whereby C3 participates in opsoniza-
tion is still controversial. The importance of C3b in promoting 
adherence of sensitized erythrocytes or bacteria to phagocytic 
cells is not disputed; however, whether C3b alone is sufficient 
to promote phagocytosis or whether it can only act synergisti-
cally with IgG to induce ingestion by neutrophils or ma~ro­
phages is open to question. The phagocytosis of EAigMC1-3b 
[39] and of various strains of staphylococci [51] appears to be 
wholly dependent on opsonization by C3b. Also, both the phag-
ocytosis and killing of bacteria have been found to occm with 
agammaglobulinemic human serum [52]. However, different 
experiments indicate that C3 and IgG have separate roles in 
the steps of phagocytosis: C3 primarily mediates the binding of 
the particle via complement receptors while IgG, through its 
Fe fragment, directly stimulates particle ingestion but is rela-
tively inefficient at inducing particle binding [53-57]. Fmther-
more, a marked synergy is thought to exist between C3 and IgG 
in inducing adherence and phagocytosis. The C3d fragment of 
C3 also can function as an opsonin [56] if the phagocyte has the 
appropriate membrane receptor. 
There is a qualitative difference in the function of comple-
ment receptors between nonactivated and activated mouse 
peritoneal macrophages [58]. Nonactivated macrophages bind 
but do not ingest EAigMC3 (made with mouse serum) , whereas 
activated macrophages both bind and ingest EAigMC3. The 
opsonization of erythrocytes coated with complement may dif-
fer from the opsonization of bacteria, especially because of 
varying densities of complement on the surface and the relative 
sizes of the particles coated. Therefore, results of phagocytosis 
experiments should be interpreted according to the functional 
state of the various types of phagocytic cells and the types of 
particle to be ingested. 
There may be a functional basis for the fact that EAigM and 
EAigMC3 adhere to the macrophages without being ingested, 
as Mantovani, Rabinovitch, and Nussensweig [53) have sug-
gested. In the primary immune response when only IgM is 
present, the immune complexes would tend to remain on the 
surfaces of the macro phages and thus would be in a position to 
stimulate immunocompetent cells. In the secondary response 
when EAigG or EAigGC3 predominate, the complexes would 
tend to be more rapidly interiorized and degraded by the 
mononuclear phagocytes. 
The interaction between C3b and the C3b receptor may also 
promote and perhaps even determine the cytolytic potential of 
inflammatory cells. Yamamura and Valdimarsson [50] have 
shown that Candida albicans opsonized with C3-deficient se-
rum is ingested by human polymorphonuclear leukocytes but 
is not killed unless purified C3 is added. Guinea pig C3b has 
been shown to interact with guinea pig and mouse macro phages 
in culture to produce a time- and dose-dependent release of 
lysosomal enzymes, without cell "suicide" or the release of such 
other enzymes as lactate dehydrogenase [59]. Also, attachment 
of C3b to the C3b receptor or human macrophages can "angrify" 
macrophages and thereby increase their content of lysosomal 
enzymes within the endoplasmic reticulum and enhance the 
bacteriocidal properties of the cells [60]. The stimulated mac-
rophages release enzymes that can, in tmn, cleave C3 and thus 
generate more C3b, which then induces fw·ther enzyme release. 
This amplification system may explain how macrophages me-
diate inflammation, causing tissue damage and degeneration 
while retaining their own viability. Furthermore, accumulation 
of macrophages at the site of an allergic reaction may be 
mediated by C3b, either directly or through a mononuclear cell 
chemotactic factor released by B lymphocytes after interaction 
with its C3b receptor [61]. 
There is some controversy about whether or not C3b alone 
is sufficient to stimulate the release of superoxide anion (02 - ) 
of oxidative metabolism [57,60], although it is agreed that Fe 
alone is sufficient to stimulate oxidative metabolism as well as 
degranulation, and that there is synergy so that binding of both 
C3b and Fe to their respective receptors causes enhancement 
of both cytotoxic mechanisms [57). 
A special role in the induction of the immune response has 
been demonstrated through observation of the C3b receptor on 
dendritic cells found in the thymus-dependent areas of lymph 
nodes [62) and the spleen [63]. The attachment of immune 
complexes to these cells requires both antibody and comple-
ment [64,65]. Localization of protein antigen is a prerequisite 
for the development of germinal centers of B cell memory. This 
localization, however, does not occur in tolerant animals or 
those chronically depleted of circulating C3 by treatment with 
cobra venom factor [64,65], and in the latter case, germinal 
centers do not form [59]. In mice chronically depleted of C3, B 
cell memory to the antigen does not develop, probably because 
of impaired precursor proliferation after priming [64]. The 
development of B memory cells appears to involve the forma-
tion of antigen-antibody-C3 complexes on dendritic cells in 
lymphoid follicles. Fmthermore, C3 may stabilize the antigen 
bridge between dendritic cells and virgin precursors in a manner 
similar to that suggested for C3 in T-cell-dependent B lympho-
cytic triggering of antibody production. 
The effect of the complement receptor in the humoral im-
mune response has been reviewed by Pepys [66]. The in vivo 
administration of cobra venom factor causes depletion of 
plasma C3 and suppresses the IgG, IgA, and IgE responses to 
thymus-dependent antigens; however, the IgM response is less 
depressed. In fact, lymphocytes without a C3b receptor can 
produce 7S (but not 19S) antibody to aT-independent antigen 
in vivo [67] . The role of C3 in the thymus-dependent antibody 
response may be by promoting bridging between antigen-carry-
ing macrophages and/or T and B lymphocytes [67,68] or by 
enhancing the binding of antigen to the B cell swface. On the 
other hand, Waldmann and Lachmann [69) deny that C3 has 
any necessary role in the in vitro antibody response. The fact 
that there are no C3 receptors on differentiated plasma cells 
[28,29] may substantiate their conclusion. 
Perhaps this complement receptor has additional functions 
in the stimulation of B lymphocytes leading to clonal prolifer-
ation and differentiation. The stimulation of DNA synthesis 
and blast formation in murine lymphocyte cultures by pure 
fluid-phase C3b has been demonstrated [70]. Whether or not 
C3b per se has a mitogenic effect on lymphocytes may depend 
on the methods and quantities of C3b used. However, failure to 
find any lymphocyte abnormality in C3biNA-deficient patients 
with high levels of continuously circulating C3b suggests that 
this phenomenon is hot of major importance in vivo [71]. 
The function of the complement receptor on the LCs is still 
a matter of conjecture. The fact that LCs are significant to the 
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primary immune response was first suggested by Prunieras 
[72). It is known that LCs express Ia antigens [73] that play a 
role in triggering the mixed lymphocyte reaction [74] and that 
are required for collaboration between T and B lymphocytes 
[75] and between macrophages and T cells [76]. Stingl et al 
[77,78) have shown that LCs are antigen-presenting cells and 
do stimulate the mixed lymphocyte reaction. (Silberberg-Sin-
akin et al [79) demonstrated that LCs migrate from the epider-
mis to the lymph nodes during sensitization.) Furthermore, 
there is opposition of lymphoid cells to LCs and damage to LCs 
at sites of specific antigenic challenge in allergic contact hyper-
sensitivity but not in primary irritant dermatitis [80]. In C4-
deficient guinea pigs there is no damage to LCs as in normal 
animals after injection of antigen-antibody complexes, and more 
LCs are seen in draining lymph nodes with some types of 
immune complexes. We suggest that complement receptors 
modulate the release of lytic enzymes and the interaction of th e 
LCs with lymphocytes and other cell types. 
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